Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Aug;96(8):1128-35.
doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12.

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study

Steven Le Gouill  1 , Sophie De Guibert, Lucie Planche, Pauline Brice, Jehan Dupuis, Guillaume Cartron, Achiel Van Hoof, Olivier Casasnovas, Emmanuel Gyan, Hervé Tilly, Christophe Fruchart, Eric Deconinck, Olivier Fitoussi, Lauris Gastaud, Vincent Delwail, Jean Gabarre, Rémy Gressin, Michel Blanc, Charles Foussard, Gilles Salles; GELA and GOELAMS
Affiliations
Clinical Trial

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study

Steven Le Gouill et al. Haematologica. 2011 Aug.

Abstract

Background: We analyzed detailed characteristics and salvage treatment in 175 follicular lymphoma patients from the FL2000 study who were in progression after first-line therapy with or without addition of rituximab to chemotherapy and interferon.

Design and methods: The impact of using autologous stem cell transplantation and/or rituximab administration at first progression was investigated, taking into account initial therapy. With a median follow up of 31 months, 3-year event free and overall survival rates after progression were 50% (95%CI 42-58%) and 72% (95%CI 64-78%), respectively.

Results: The 3-year event free rate of rituximab re-treated patients (n=112) was 52% (95%CI 41-62%) versus 40% (95%CI 24-55%) for those not receiving rituximab second line (n=53) (P=0.075). There was a significant difference in 3-year overall survival between patients receiving autologous stem cell transplantation and those not: 92% (95%CI 78-97%) versus 63% (95%CI 51-72%) (P=0.0003), respectively. In multivariate analysis, both autologous stem cell transplantation and period of progression/relapse affected event free and overall survival.

Conclusions: Regardless of front-line rituximab exposure, this study supports incorporating autologous stem cell transplantation in the therapeutic approach at first relapse for follicular lymphoma patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient outcome calculated from first progression (n=175). (A) Event-free survival; the 3- and 5-year EFS rates are 50% (95% CI; 42–58%) and 26% (95% CI; 14–39%), respectively. (B) Overall survival; the 3- and 5-year OS rates are 72% (95% CI; 64–78%) and 52% (95% CI; 36–66%), respectively.
Figure 2.
Figure 2.
Outcome of patients (under the age of 70 years) according to transplantation at first progression: ----transplanted patients (n=42); —— non-transplanted patients (n=111). (A) Event-free survival (P=0.0005). (B) Overall survival (P=0.0003).
Figure 3.
Figure 3.
Outcome of patients (under the age of 70 years) according to front-line therapy and use of transplantation at first progression: ---- transplanted patients and —— non-transplanted patients. (A) Event-free survival of patients failing CHVP-I (P=0.002). (B) Overall survival of patients failing CHVP-I (P=0.005). (C) Event-free survival of patients failing R-CHVP-I (P=0.052). (D) Overall survival of patients failing R-CHVP-I (P=0.052).
Figure 4.
Figure 4.
Outcome of patients (under the age of 70 years) according to progression period and use of transplantation at first progression: ---- transplanted patients and —— non-transplanted patients. (A) Event-free survival of primary refractory patients (P=0.002). (B) Event-free survival of patients who progressed or relapsed after first-line treatment completion: (P=0.011).
See this image and copyright information in PMC

References

    1. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24(10):1582–9. - PubMed
    1. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008;168(5):469–76. - PubMed
    1. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986–92. - PubMed
    1. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32. - PubMed
    1. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–86. - PubMed

Publication types

MeSH terms

Substances